Results 131 to 140 of about 6,491 (191)

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. [PDF]

Pediatr Allergy Immunol
Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N.   +5 more
europepmc   +1 more source

Recommendations on Respiratory Syncytial Virus (RSV) Immunization Strategies for Infants and Young Children in Countries with Year-Round RSV Activity. [PDF]

Vaccines (Basel)
Cheah FC, Khoo EJ, Ali A, Ismail Z, Awang RA, Ng DC, Chan PWK, Ahmad Kamar A, Chua XY, Sam JI, Abdul Manaf MR, Kassim A.   +11 more
europepmc   +1 more source

Hospitalization Outcomes of Full-Term and Premature Children Aged Less Than 2 Years Hospitalized With RSV. [PDF]

Pediatrics
Salthouse AL, Tannis A, Rutkowski RE, Weinberg GA, Szilagyi PG, Staat MA, Schlaudecker E, Halasa NB, Stewart LS, Boom JA, Sahni LC, Michaels MG, Schuster JE, Selvarangan R, Klein EJ, Englund JA, Williams JV, Toepfer A, Moline HL, Dawood FS.   +19 more
europepmc   +1 more source

Mutational constraints on RSV F and its neutralization by antibodies. [PDF]

Nature
Simonich CAL, McMahon TE, Juviler G, Kampman L, Chu HY, Bloom JD.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. [PDF]

Infect Dis Ther
Yarnoff B, Beuvelet M, Soudani S, Neary MP, Hodges EN, Chit A, Tribaldos M, Gabriel V, Musci R, Geurtsen J, Krilov LR.   +10 more
europepmc   +1 more source

Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein. [PDF]

EMBO Mol Med
Wang Q, Ke X, Li E, Hong D, Cheng Z, Li H, Zhang J, Jin T, Gong R, Shu B, Chiu S.   +10 more
europepmc   +1 more source

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants. [PDF]

Cureus
Chamarthi S, Gupta S, Chamarthi VS.
europepmc   +1 more source

New Drugs: Palivizumab

Australian Prescriber, 1999
openaire   +1 more source

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

JAMA Netw Open
Sauré D, Torres JP, Goic M, Thraves C, Pacheco J, Burgos J, Zgheib A, Del Solar F, Neira I, O'Ryan M, Basso LJ.   +10 more
europepmc   +1 more source